The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation

Mayo Clinic Proceedings

Volumn 79, Issue 7, 2004, Pages 904-913

  Ezekowitz, Michael D ^a   Falk, Rodney H ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AF = atrial fibrillation; AFFIRM = Atrial Fibrillation Follow up Investigation of Rhythm Management; CAA = cerebral amyloid angiopathy; GI = gastrointestinal; ICH = Intracerebral hemorrhage; INR = International normalized ratio

Indexed keywords

1 (6 AMINO 2 METHYL 3 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 PHENETHYLAMINO 6 METHYL 2 PYRAZINONE; 1 [3 (4 AMIDINOPHENYL) 2 (1,2,3,4 TETRAHYDRO 2 METHYL 7 ISOQUINOLINYLSULFONAMIDO)PROPIONYL] 1,2,3,6 TETRAHYDRO 4 METHYLPICOLINIC ACID; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DABIGATRAN ETEXILATE; DALTEPARIN; DIGOXIN; ENOXAPARIN; HEPARIN; HIRULOG; LEPIRUDIN; PHENPROCOUMON; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

AGE; ANTICOAGULANT THERAPY; BLEEDING; CANCER STAGING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART RHYTHM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTERNATIONAL STANDARD UNIT; LIVER TOXICITY; PUBLICATION; REVIEW; RISK FACTOR; RISK REDUCTION; STOMACH ULCER; STROKE;

EID: 3042758487     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.7.904     Document Type: Review

References (93)

1. Centers for Medicare and Medicaid Services. Quality improvement organizations: stroke project [Web site]. Available at: http://cms.hhs.gov/qio/ 1a1-b1.asp. Accessed August 11, 2002.
2. Wolf PA, Singer DE. Preventing stroke in atrial fibrillation. Am Fam Physician. 1997;56:2242-2250.
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
4. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147: 1561-1564.
6. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-484.
7. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-179.
8. Ezekowitz MD, Bridgers SL, James KE, et al, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published correction appears in N Engl J Med. 1993;328:148]. N Engl J Med. 1992;327: 1406-1412.
9. Ezekowitz MD, Bridgers SL, James KE, et al, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published correction appears in N Engl J Med. 1993;328:148]. N Engl J Med. 1992;327: 1406-1412.
10. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
11. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
12. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
13. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
14. Atwood JE, Albers GW. Anticoagulation and atrial fibrillation. Herz. 1993;18:27-38,
15. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
16. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation. (ATRIA) study. Ann Intern Med. 1999;131:927-934.
17. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1266.
18. American College of Physicians. Guidelines for medical treatment for stroke prevention. Ann Intern Med. 1994;121:54-55.
19. Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1998;51:671-673.
20. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiogruphy and Electrophysiology, American Heart Association. Circulation. 1996;93:1262-1277.
21. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(I, suppl):194S-206S.
22. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
23. American College of Chest Physicians. Sixth ACCP Consensus Conference on Antithrombotic Therapy: Quick Reference Guide for Clinicians. Northbrook, III: American College of Chest Physicians; 2001.
24. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346-349.
25. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
26. Van Gelder IC, Hagens VE, Bosker HA, et al, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
27. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
28. Carlsson J, Miketic S, Windeler J, et al, STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:11690-1696.
29. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789-1794.
30. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001;119(1, suppl):22S-38S.
31. Palareti G, Leali N, Coccheri S, et al, Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
32. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 Study. Arch Intern Med. 1999;159:1322-1328.
33. Poli D, Antonucci E, Lombardi A, et al. Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic. Ital Heart J. 2003;4:44-47.
34. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med. 2002;113:42-51.
35. Labovitz DL, Sacco RL. Intracerebral hemorrhage: update. Curr Opin Neurol. 2001;14:103-108.
36. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
37. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002;162:541-550.
38. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685.
39. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571-576.
40. Inagawa T. What are the actual incidence and mortality rates of intracerebral hemorrhage? Neurosurg Rev. 2002;25:237-246.
41. Arboix A, Comes E, Garcia-Eroles L, et al. Site of bleeding and early outcome in primary intracerebral hemorrhage. Acta Neurol Scand. 2002;105: 282-288.
42. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
43. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001;119(1, suppl):108S-121S.
44. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830-1835.
45. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000;15:56-67.
46. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-691.
47. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
48. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med. 2001;161:2125-2128.
49. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises [published correction appears in N Engl J Med. 1996; 335:1167]. N Engl J Med. 1996;335:189-196. Case 22-1996.
50. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises [published correction appears in N Engl J Med. 1996; 335:1167]. N Engl J Med. 1996;335:189-196. Case 22-1996.
51. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology. 2000;20:8-22.
52. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55:947-951.
53. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000; 342:240-245.
54. Greenberg SM, O'Donnell HC, Schaefer PW, Kraft E. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology. 1999;53:1135-1138.
55. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol. 1987; 44:21-23.
56. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
57. Gorter JW, Stroke Prevention In Reversible Ischemia Trial (SPIRIT), European Atrial Fibrillation Trial (EAFT) Study Groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology. 1999;53:1319-1327.
58. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000; 160:41-46.
59. Cohen N, Almoznino-Sarafian D, Alon I, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31:1217-1222.
60. Bungard TJ, Ghali WA, McAlister FA, et al. Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation [letter]. CMAJ. 2001;165:301-302.
61. McNulty SJ, Hutchinson D, Hardy KJ. Implementation of antithrombotic management in atrial fibrillation. Postgrad Med J. 2000;76:783-786.
62. Gaughan GL. The use of practitioner education and a warfarin monitoring service to improve anticoagulation practices [letter]. Arch Intern Med. 2000;160:2401-2402.
63. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol. 2002;25:447-454.
64. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med. 2003;163:1580-1586.
65. Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093-2100.
66. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med. 1997;157:978-984.
67. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001;161:2458-2463.
68. Bellelli G, Barbisoni P, Gusmeri A, Sabatini T, Rozzini R, Trabucchi M. Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy? [letter]. J Am Geriatr Soc. 1999;47:1034-1035.
69. Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31:822-827.
70. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Under-utilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J. 1999;137:307-312.
71. Protheroe J, Fahey T, Montgomery AA, Peters TI. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380-1384.
72. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke. 2002;33:238-242.
73. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA. 1999;282:737-743.
74. Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37:34-39.
75. Nadar S, Begum N, Kaur B, Sandhu S, Lip GY. Patients' understanding of anticoagulant therapy in a multiethnic population. J R Soc Med. 2003;96:175-179.
76. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. Ann Intern Med. 2000;133:687-695.
77. Matchar DB, McCrory DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41-53.
78. Taylor F, Ramsay M, Voke J, Cohen H. Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation [letter]. BMJ. 1993;307:1493.
79. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995;15:732-739.
80. Lee YP, Schommer JC. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions. Am J Health Syst Pharm. 1996;53:1580-1583.
81. Ansell JE. Anticoagulation management as a risk factor for adverse events: grounds for improvement. J Thromb Thrombolysis. 1998;5(suppl 1):13-18.
82. Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001;7:195-204.
83. Ferguson JJ. Low molecular weight heparins and glycoprotein IIb/IIIa antagonists. J Interv Cardiol. 2002;15:147-154.
84. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol. 2002;39:187-196.
85. Berkowitz SD. Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. Am Heart J. 2001;142:7-13.
86. Eriksson BI, Agnelli G, Cohen AT, et al, METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89:288-296.
87. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721.
88. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S, THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003;1:41-47.
89. Wallentin L, Wilcox RG, Weaver WD, et al, ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.
90. Petersen P, Grind M, Adler J, SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
91. Olsson SB, Petersen P, SPORTIF II and IV Investigators. Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients [abstract]. Eur Heart J. 2002;23(suppl):239. Abstract 1293.
92. Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-438.
93. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med. 2003;254:322-334.